NCT03036098 2026-03-06
CheckMate901
Bristol-Myers Squibb
Phase 3 Active not recruiting
Clinical Trials
34 trialsNCT06097728 2026-03-04
eVOLVE-Meso
AstraZeneca
Phase 3 Recruiting
NCT04039607 2026-02-19
CheckMate 9DW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03143153 2026-02-17
CheckMate 648
Bristol-Myers Squibb
Phase 3 Completed
NCT02998528 2026-01-06
CheckMate 816
Bristol-Myers Squibb
Phase 3 Completed
NCT03215706 2025-12-17
CheckMate 9LA
Bristol-Myers Squibb
Phase 3 Completed
NCT02477826 2025-10-30
CheckMate 227
Bristol-Myers Squibb
Phase 3 Completed
NCT03520686 2025-10-16
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Active not recruiting
NCT04008030 2025-10-03
CheckMate 8HW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03937219 2025-09-10
COSMIC-313
Exelixis
Phase 3 Active not recruiting
NCT02872116 2025-08-07
CheckMate649
Bristol-Myers Squibb
Phase 3 Completed
NCT02231749 2025-06-26
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Phase 3 Completed
NCT03141177 2025-06-06
CheckMate 9ER
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT01844505 2025-05-21
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
Bristol-Myers Squibb
Phase 3 Completed
NCT02388906 2025-04-24
CheckMate 238
Bristol-Myers Squibb
Phase 3 Completed
NCT03138512 2024-12-18
CheckMate 914
Bristol-Myers Squibb
Phase 3 Completed
NCT04340193 2024-11-26
CheckMate 74W
Bristol-Myers Squibb
Phase 3 Completed
NCT05144854 2024-09-05
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Ono Pharmaceutical Co. Ltd
Phase 3 Active not recruiting
NCT02899299 2024-05-21
CheckMate743
Bristol-Myers Squibb
Phase 3 Completed
NCT02864251 2023-09-28
CheckMate722
Bristol-Myers Squibb
Phase 3 Completed
NCT03302234 2023-09-26
KEYNOTE-598
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02741570 2023-09-21
CheckMate 651
Bristol-Myers Squibb
Phase 3 Completed
NCT02538666 2023-01-05
CheckMate 451
Bristol-Myers Squibb
Phase 3 Completed
NCT03445533 2022-11-08
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Idera Pharmaceuticals, Inc.
Phase 3 Terminated
NCT02714218 2022-06-24
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Bristol-Myers Squibb
Phase 3 Completed
NCT03068455 2021-09-20
CheckMate 915
Bristol-Myers Squibb
Phase 3 Completed
NCT02599402 2021-06-15
CheckMate 401
Bristol-Myers Squibb
Phase 3 Completed
NCT01450761 2020-07-08
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
Bristol-Myers Squibb
Phase 3 Completed
NCT01866319 2020-06-02
MK-3475-006
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02545075 2020-05-19
A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
Bristol-Myers Squibb
Phase 3 Completed
NCT03048136 2018-04-17
CheckMate 955
Bristol-Myers Squibb
Phase 3 Withdrawn
NCT00861614 2016-09-30
Study of Immunotherapy to Treat Advanced Prostate Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT01057810 2016-08-18
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT00094653 2011-07-11
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Bristol-Myers Squibb
Phase 3 Completed